Abstract
Monoclonal antibodies can mediate antitumor activity by multiple mechanisms. They can bind directly to tumor receptors resulting in tumor cell death, or can bind to soluble growth factors, angiogenic factors, or their cognate receptors blocking signals required for tumor cell growth or survival. Monoclonal antibodies, upon binding to tumor cell, can also engage the host’s immune system to mediate immune-mediated destruction of the tumor. The Fc portion of the antibody is essential in engaging the host immune system by fixing complement resulting in complement-mediated cytotoxicity (CDC) of the tumor, or by engaging Fc receptors for IgG (FcγR) expressed by leukocytes leading to antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) of tumor cells. Antibodies whose Fc portion preferentially engage activating FcγRs have shown greater inhibition of tumor growth and metastasis. Monoclonal antibodies can also stimulate the immune system by binding to targets expressed on immune cells. These antibodies may stimulate antitumor immunity by antagonizing a negative regulatory signal, agonizing a costimulatory signal, or depleting immune cells that are inhibitory. The importance of Fc:FcγR interactions in antitumor therapy for each of these mechanisms have been demonstrated in both mouse models and clinical trials and will be the focus of this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abès R et al (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6):926–934
Albanell J, Baselga J (1999) Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer Drugs Today (Barc) 35:931–946
Amiri-Kordestani L et al. (2014a) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer Clin Cancer Res 20:4436–4441 https://doi.org/10.1158/1078-0432.ccr-14-0012
Amiri-Kordestani L et al. (2014b) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer Clin Cancer Res 20:5359–5364 https://doi.org/10.1158/1078-0432.ccr-14-1268
Barnhart BC, Quigley M (2017) Role of Fc-FcgammaR interactions in the antitumor activity of therapeutic antibodies. Immunol Cell Biol 95:340–346. https://doi.org/10.1038/icb.2016.121
Bartholomaeus P et al (2014) Cell contact-dependent priming and Fc interaction with CD32 + immune cells contribute to the TGN1412-triggered cytokine response. J Immunol 192:2091–2098. https://doi.org/10.4049/jimmunol.1302461
Bezman NA et al (2017) PD-1 blockade enhances elotuzumab efficacy in mouse tumor models blood advances 1:753–765
Blair HA (2018) Atezolizumab: A Review in Previously Treated Advanced Non-Small. Cell Lung Cancer Target Oncol 13:399–407. https://doi.org/10.1007/s11523-018-0570-5
Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M (2001) Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 167:5517–5521
Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643–646
Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–5649. https://doi.org/10.1182/blood-2012-01-380121
Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725. https://doi.org/10.1182/blood-2008-09-179754
Bulliard Y et al (2013) Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210:1685–1693. https://doi.org/10.1084/jem.20130573
Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL (2014) OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy Immunol Cell Biol 92:475–480. https://doi.org/10.1038/icb.2014.26
Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71:1093–1104. https://doi.org/10.2165/11594010-000000000-00000
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758
Cheney CM et al (2014) Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 6:749–755. https://doi.org/10.4161/mabs.28282
Chuntharapai A et al (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891–4898
Clavijo PE et al (2017) Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget 8:55804–55820. https://doi.org/10.18632/oncotarget.18437
Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 20:585–612. https://doi.org/10.1016/j.hoc.2006.02.010
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446. https://doi.org/10.1038/74704
Coe D, Begom S, Addey C, White M, Dyson J, Chai JG (2010) Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59:1367–1377. https://doi.org/10.1007/s00262-010-0866-5
Collins SM et al (2013) Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62:1841–1849. https://doi.org/10.1007/s00262-013-1493-8
Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28:285–295. https://doi.org/10.1016/j.ccell.2015.08.004
Dhillon S (2015) Dinutuximab: first global approval. Drugs 75:923–927. https://doi.org/10.1007/s40265-015-0399-5
Dienstmann R, Tabernero J (2010) Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer Curr Opin Investig. Drugs 11:1434–1441
DiLillo DJ, Ravetch JV (2015) Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions cancer. Immunol Res 3:704–713. https://doi.org/10.1158/2326-6066.CIR-15-0120
Ferrara N, LeCouter J, Lin R, Peale F (2004) EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors. Biochim Biophys Acta 1654:69–78. https://doi.org/10.1016/j.bbcan.2003.07.001
Forero-Torres A et al (2012) Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 18:1395–1403. https://doi.org/10.1158/1078-0432.ccr-11-0850
Gbadamosi M, Meshinchi S, Lamba JK (2018) Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. Future Oncol. https://doi.org/10.2217/fon-2018-0325
Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577–583. https://doi.org/10.1634/theoncologist.12-5-577
Goede V et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110. https://doi.org/10.1056/NEJMoa1313984
Goldberg RM (2005) Cetuximab. Nat Rev Drug Discov Suppl:S10–11
Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.Expert Rev Anticancer Ther 2:485–493. https://doi.org/10.1586/14737140.2.5.485
He LZ et al (2013) Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 191:4174–4183. https://doi.org/10.4049/jimmunol.1300409
Hsi ED et al (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775–2784. https://doi.org/10.1158/1078-0432.ccr-07-4246
Jakobovits A (1998) The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Expert Opin Investig Drugs 7:607–614. https://doi.org/10.1517/13543784.7.4.607
Jakubowiak AJ et al (2016) Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective J. Med Econ 19:1061–1074. https://doi.org/10.1080/13696998.2016.1194278
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525. https://doi.org/10.1038/321522a0
Kazandjian D et al (2016) FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21:634–642. https://doi.org/10.1634/theoncologist.2015-0507
Kerr DJ (2004) Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 1:39–43. https://doi.org/10.1038/ncponc0026
Kim ES (2017) Avelumab: first global approval. Drugs 77:929–937. https://doi.org/10.1007/s40265-017-0749-6
Kim YH et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(18)30379-6
Klein C et al (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5:22–33. https://doi.org/10.4161/mabs.22771
Ko K et al (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory. T cells J Exp Med 202:885–891. https://doi.org/10.1084/jem.20050940
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495
Kohrt HE et al (2012) Combination strategies to enhance antitumor ADCC. Immunotherapy 4:511–527. https://doi.org/10.2217/imt.12.38
Krejcik J et al (2016) Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384–394
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736
Lehmann B et al (2017) Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci Immunol 2.pii: eaah6413. https://doi.org/10.1126/sciimmunol.aah6413
Li F, Ravetch JV (2011) Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333:1030–1034. https://doi.org/10.1126/science.1206954
Li F, Ravetch JV (2012) Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci U S A 109:10966–10971. https://doi.org/10.1073/pnas.1208698109
Li F, Ravetch JV (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc Natl Acad Sci U S A 110:19501–19506. https://doi.org/10.1073/pnas.1319502110
Lonial S et al (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373:621–631. https://doi.org/10.1056/NEJMoa1505654
Lu D et al (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278:43496–43507. https://doi.org/10.1074/jbc.m307742200
Lundin J et al (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 16:3257–3263. https://doi.org/10.1200/jco.1998.16.10.3257
Mahne AE et al (2017) Dual roles for regulatory T-cell depletion and costimulatory signaling in agonistic GITR targeting for tumor immunotherapy. Cancer Res 77:1108–1118. https://doi.org/10.1158/0008-5472.CAN-16-0797
Maloney DG et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195
Markham A (2016) Elotuzumab: first global approval drugs 76:397–403. https://doi.org/10.1007/s40265-016-0540-0
McKeage K (2016) Daratumumab: first global approval. Drugs 76:275–281. https://doi.org/10.1007/s40265-015-0536-1
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851–6855
Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510–1512
Ogura M et al (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32:1157–1163. https://doi.org/10.1200/jco.2013.52.0924
Osterborg A et al (2016) Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia Leuk. Lymphoma 57:2037–2046. https://doi.org/10.3109/10428194.2015.1122783
Overdijk MB et al (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. In: MAbs, vol 2. Taylor & Francis, pp 311–320
Park KU et al (2010) Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients. J Immunother 33:945–955. https://doi.org/10.1097/CJI.0b013e3181f71b81
Pierpont TM, Limper CB, Richards KL (2018) Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Front Oncol 8:163. https://doi.org/10.3389/fonc.2018.00163
Plitas G et al (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45:1122–1134. https://doi.org/10.1016/j.immuni.2016.10.032
Poole RM (2014) Pembrolizumab: first global approval. Drugs 74:1973–1981. https://doi.org/10.1007/s40265-014-0314-5
Poole RM, Vaidya A (2014) Ramucirumab: first global approval. Drugs 74:1047–1058. https://doi.org/10.1007/s40265-014-0244-2
Ravetch JV, Lanier LL (2000) Immune inhibitory receptors Science 290:84–89
Salles G et al. (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119:5126–5132. https://doi.org/10.1182/blood-2012-01-404368
Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32–42. https://doi.org/10.1158/2326-6066.cir-13-0013
Serna-Gallegos TR, La-Fargue CJ, Tewari KS (2018) The ecstacy of gold: patent expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab Recent Pat. Biotechnol 12:101–112. https://doi.org/10.2174/1872208311666171122152131
Shields RL et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–26740. https://doi.org/10.1074/jbc.m202069200
Shirley M (2017) Olaratumab: first global approval. Drugs 77:107–112. https://doi.org/10.1007/s40265-016-0680-2
Simpson TR et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710. https://doi.org/10.1084/jem.20130579
Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV (2012) Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A 109:6181–6186. https://doi.org/10.1073/pnas.1203954109
Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71:2892–2900. https://doi.org/10.1158/0008-5472.can-10-4246
Syed YY (2017) Durvalumab: first global approval. Drugs 77:1369–1376. https://doi.org/10.1007/s40265-017-0782-5
Tai YT et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood 112:1329–1337. https://doi.org/10.1182/blood-2007-08-107292
Tam SH et al (2017) Functional, biophysical, and structural characterization of human IgG1 and IgG4 variants with ablated immune functionality. Antibodies 6:1–34
Taylor LD et al (1992) A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res 20:6287–6295
Tobinai K et al (2011) Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci 102:432–438. https://doi.org/10.1111/j.1349-7006.2010.01809.x
Tuaillon N, Taylor LD, Lonberg N, Tucker PW, Capra JD (1993) Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts. Proc Natl Acad Sci U S A 90:3720–3724
Tvito A, Rowe JM (2017) Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Expert Opin Biol Ther 17:1557–1564. https://doi.org/10.1080/14712598.2017.1387244
van der Veer MS et al (2011) The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 1:e41
Wasiuk A et al (2017) CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy. J Immunol 199:4110–4123. https://doi.org/10.4049/jimmunol.1700606
Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033–1040. https://doi.org/10.1016/S0140-6736(09)60251-8
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947. https://doi.org/10.1200/JCO.2003.05.013
White AL et al (2011) Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187:1754–1763. https://doi.org/10.4049/jimmunol.1101135
Xu Y et al (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 171:562–568
Yamane-Ohnuki N, Satoh M (2009) Production of therapeutic antibodies with controlled fucosylation. MAbs 1:230–236
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821. https://doi.org/10.1056/nejmoa1002965
Acknowledgements
The authors thank Catherine A. Bolger for her review and editing, and Alan J. Korman for his critical reading and insightful perspective on this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Graziano, R.F., Engelhardt, J.J. (2019). Role of FcγRs in Antibody-Based Cancer Therapy. In: Ravetch, J., Nimmerjahn, F. (eds) Fc Mediated Activity of Antibodies. Current Topics in Microbiology and Immunology, vol 423. Springer, Cham. https://doi.org/10.1007/82_2019_150
Download citation
DOI: https://doi.org/10.1007/82_2019_150
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31052-3
Online ISBN: 978-3-030-31053-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)